Cadia Private Client »

Halozyme Therapeutics shares owned by Cadia Private Client

Quarter-by-quarter ownership of Halozyme Therapeutics (HALO) shares owned by Cadia Private Client from 13F filings

Historical chart of Cadia Private Client investment in Halozyme Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Halozyme Therapeutics held by Cadia Private Client consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Halozyme Therapeutics by Cadia Private Client

Quarter filed Position value Share count Share price at filing
2026-03-31 $1.4M 22k 64.63
2025-12-31 $1.4M 22k 67.30

More positions owned by Cadia Private Client

Vanguard Index Fds S&p 500 Etf Shs (VOO)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Schwab Strategic Tr Int-trm U.s Tres (SCHR)
Ishares Tr Core S&p Ttl Stk (ITOT)
Schwab Strategic Tr Us Dividend Eq (SCHD)
Ishares Tr Core Div Grwth (DGRO)
Fidelity Merrimack Str Tr Total Bd Etf (FBND)
Ishares Tr Core Us Aggbd Et (AGG)
Ishares Tr Trust Ishare 0-1 (SHV)
Ishares Tr TRS FLT RT BD (TFLO)
Ishares Tr Core S&p Mcp Etf (IJH)
JPMorgan Chase & Co. (JPM)
Ishares Tr Msci Usa Qlt Fct (QUAL)
Ishares Tr Us Treas Bd Etf (GOVT)
NVIDIA Corporation (NVDA)

View all positions for Cadia Private Client

Top funds holding Halozyme Therapeutics

BlackRock
Vanguard Capital Management
Vanguard Portfolio Management
State Street Corporation
Invesco
Bank of America Corporation
Robeco Investment Management
Morgan Stanley
William Blair Investment Management
Geode Capital Management
Snyder Capital Management
Dimensional Fund Advisors
Arrowstreet Capital, Limited Partnership
D. E. Shaw & Co
Alliancebernstein

View all funds holding Halozyme Therapeutics